David E. I. Pyott Acquires 27,900 Shares of Alnylam Pharmaceuticals Inc. (ALNY) Stock
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) Director David E. I. Pyott acquired 27,900 shares of the business’s stock in a transaction on Thursday, October 13th. The stock was acquired at an average price of $37.00 per share, with a total value of $1,032,300.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) opened at 36.58 on Tuesday. Alnylam Pharmaceuticals Inc. has a 12 month low of $33.16 and a 12 month high of $110.75. The stock’s market cap is $3.14 billion. The firm has a 50-day moving average of $64.36 and a 200 day moving average of $65.03.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.24) by $0.19. Alnylam Pharmaceuticals had a negative net margin of 1,204.91% and a negative return on equity of 29.60%. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.09 million. During the same quarter in the prior year, the firm earned ($0.85) earnings per share. The company’s revenue for the quarter was up .2% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals Inc. will post ($4.68) EPS for the current year.
A number of analysts have recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $152.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, August 5th. Cowen and Company restated a “buy” rating and set a $150.00 price target on shares of Alnylam Pharmaceuticals in a report on Sunday, August 7th. Jefferies Group set a $86.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, September 28th. Janney Montgomery Scott assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 28th. They set a “neutral” rating and a $74.00 price target for the company. Finally, Goldman Sachs Group Inc. restated a “neutral” rating and set a $65.00 price target (up previously from $63.00) on shares of Alnylam Pharmaceuticals in a report on Wednesday, August 10th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $79.50.
Institutional investors have recently made changes to their positions in the stock. Gulf International Bank UK Ltd increased its position in shares of Alnylam Pharmaceuticals by 8.7% in the third quarter. Gulf International Bank UK Ltd now owns 25,100 shares of the biopharmaceutical company’s stock valued at $1,701,000 after buying an additional 2,000 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $522,000. Daiwa SB Investments Ltd. purchased a new position in shares of Alnylam Pharmaceuticals during the third quarter valued at about $326,000. Macquarie Group Ltd. increased its position in shares of Alnylam Pharmaceuticals by 2,138.1% in the second quarter. Macquarie Group Ltd. now owns 20,143 shares of the biopharmaceutical company’s stock valued at $1,118,000 after buying an additional 19,243 shares during the last quarter. Finally, Royal Bank of Canada increased its position in shares of Alnylam Pharmaceuticals by 63.0% in the second quarter. Royal Bank of Canada now owns 51,314 shares of the biopharmaceutical company’s stock valued at $2,847,000 after buying an additional 19,827 shares during the last quarter. 85.95% of the stock is currently owned by institutional investors and hedge funds.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.